DISCONTINUED OPERATIONS (Tables)

6 Months Ended

Jun. 30, 2017

Discontinued Operations and Disposal Groups [Abstract]

Schedule of Discontinued Operations

The Company accounted for the termination of the Pfizer Agreement and the sale of the license as a discontinued operation, in accordance with ASU No. 2014-08. The following assets and liabilities associated with the Company’s discontinued operations have been segregated and classified as assets and liabilities of discontinued operations, as appropriate, in the consolidated balance sheets as of June 30, 2017 and December 31, 2016, respectively:

	June 30, 2017		December 31, 2016
	(U.S. dollars in thousands)
CURRENT ASSETS:
Accounts receivable - Trade	$	213	$	327
Total current assets of discontinued operations	$	213	$	327

The following summarizes financial information related to the Company’s discontinued operations in the Company’s consolidated statements of operations for the six months ended June 30, 2017 and June 30, 2016:

	Six months ended June 30,
	2017		2016
		(U.S. dollars in thousands)
REVENUES			$	209
COST OF REVENUES				(373)
GROSS PROFIT				(164)
SELLING, GENERAL AND ADMINISTRATIVE EXPENSES				(25)
NET (LOSS) FOR THE PERIOD FROM DISCONTINUED  OPERATIONS			$	(189)